PURINES AND METHODS OF THEIR USE
Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
1 . A compound of formula (I):
or a pharmaceutically acceptable salt thereof,
wherein
X is NR A , S, or O;
Y is CR A or N;
R 1 is optionally substituted C 1-9 heteroaryl comprising a 5-membered ring having a nitrogen atom at position 2 relative to the bond to the core, optionally substituted pyrimidin-6-yl, or optionally substituted benzodioxanyl;
R 2 is optionally substituted C 6-10 aryl, optionally substituted C 1-9 heterocyclyl, or optionally C 1-9 substituted heteroaryl; and
R 3 is
and
each R A is independently H, optionally substituted C 1-6 alkyl, optionally substituted C 6-10 aryl, optionally substituted C 1-9 heteroaryl.
2 . The compound of claim 1 , wherein X is NR A .
3 . The compound of claim 1 , wherein Y is N.
4 . The compound of claim 1 , wherein R 3 is
5 . The compound of claim 1 , wherein the compound is of formula Ia:
or a pharmaceutically acceptable salt thereof.
6 . The compound of claim 1 , wherein R A is optionally substituted C 1-6 alkyl.
7 . The compound of claim 1 , wherein R A is H.
8 . The compound of claim 1 , wherein the compound is of formula Ib:
or a pharmaceutically acceptable salt thereof.
9 . The compound of claim 1 , wherein the compound is of formula Ic:
or a pharmaceutically acceptable salt thereof.
10 . The compound of claim 1 , wherein the compound is of formula Id:
or a pharmaceutically acceptable salt thereof.
11 . (canceled)
12 . The compound of claim 1 , wherein R 1 is optionally substituted pyrazol-1-yl.
13 . (canceled)
14 . (canceled)
15 . The compound of claim 1 , wherein R 1 is optionally substituted pyrazol-3-yl.
16 . (canceled)
17 . (canceled)
18 . The compound of claim 1 , wherein R 1 is optionally substituted pyrimidin-6-yl.
19 . The compound of claim 1 , wherein R 2 is optionally substituted C 1-9 heteroaryl.
20 . The compound of claim 19 , wherein R 2 is optionally substituted pyridyl.
21 . The compound of claim 1 , wherein R 2 is optionally substituted tetrahydropyranyl, optionally substituted dihydropyranyl, optionally substituted piperidinyl, or optionally substituted azetidinyl.
22 . (canceled)
23 . A compound of the following structure:
or a pharmaceutically acceptable salt thereof.
24 . A compound of the following structure:
or a pharmaceutically acceptable salt thereof.
25 . A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
26 . A method of treating a neurological disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
27 .- 58 . (canceled)